Fasudil reversed MCT-induced and chronic hypoxia-induced pulmonary hypertension by attenuating oxidative stress and inhibiting the expression of Trx1 and HIF-1α

Respiratory Physiology and Neurobiology

Volumn 201, Issue , 2014, Pages 38-46

  Liu, Manling ^a   Wang, Yanxia ^a   Zheng, Lianhe ^b   Zheng, Wansong ^b   Dong, Kai ^c   Chen, Shuai ^c   Zhang, Bo ^a   Li, Zhichao ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c Tianjin Chase Sun Pharmaceutical Co Ltd   (China)

Author keywords

Fasudil; Hypoxia inducible factor 1 (HIF 1 ); Oxidative stress; Pulmonary hypertension (PH); Thioredoxin 1 (Trx1)

Indexed keywords

FASUDIL; HYDROGEN PEROXIDE; HYDROXYL RADICAL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MALONALDEHYDE; MONOCROTALINE; SUPEROXIDE DISMUTASE; THIOREDOXIN REDUCTASE 1; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; THIOREDOXIN; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTERIOLE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HEART RIGHT VENTRICLE HYPERTROPHY; HEMODYNAMICS; HYPOXIA; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; SYSTOLIC BLOOD PRESSURE; UPREGULATION; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; ANIMAL; ANOXIA; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; HYPERTENSION, PULMONARY; METABOLISM; SPRAGUE DAWLEY RAT;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANALYSIS OF VARIANCE; ANIMALS; ANOXIA; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HEMODYNAMICS; HYDROGEN PEROXIDE; HYPERTENSION, PULMONARY; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MALONDIALDEHYDE; MONOCROTALINE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE; THIOREDOXINS; VASODILATOR AGENTS;

EID: 84904718340     PISSN: 15699048     EISSN: 18781519     Source Type: Journal    
DOI: 10.1016/j.resp.2014.06.001     Document Type: Article

References (44)

1. Abe K., Shimokawa H., Morikawa K., Uwatoku T., Oi K., Matsumoto Y., Hattori T., Nakashima Y., Kaibuchi K., Sueishi K., Takeshit A. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ. Res. 2004, 94:385-393.
2. Abe K., Tawara S., Oi K., Hizume T., Uwatoku T., Fukumoto Y., Kaibuchi K., Shimokawa H. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J. Cardiovasc. Pharmacol. 2006, 48:280-285.
3. Bonnet S., Michelakis E.D., Porter C.J., Andrade-Navarro M.A., Thebaud B., Bonnet S., Haromy A., Harry G., Moudgil R., McMurtry M.S., Weir E.K., Archer S.L. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 2006, 113:2630-2641.
4. Bowers R., Cool C., Murphy R.C., Tuder R.M., Hopken M.W., Flores S.C., Voelkel N.F. Oxidative stress in severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2004, 169:764-769.
5. Callister M.E., Burke-Gaffney A., Quinlan G.J., Nicholson A.G., Florio R., Nakamura H., Yodoi J., Evans T.W. Extracellular thioredoxin levels are increased in patients with acute lung injury. Thorax 2006, 61:521-527.
6. Cowan K.N., Heilbut A., Humpl T., Lam C., Ito S., Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat. Med. 2000, 6:698-702.
7. DeMarco V.G., Habibi J., Whaley-Connell A.T., Schneider R.I., Heller R.L., Bosanquet J.P., Hayden M.R., Delcour K., Cooper S.A., Andresen B.T., Sowers J.R., Dellsperger K.C. Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H2659-H2668.
8. Dorfmuller P., Chaumais M.C., Giannakouli M., Durand-Gasselin I., Raymond N., Fadel E., Mercier O., Charlotte F., Montani D., Simonneau G., Humbert M., Perros F. Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. Respir. Res. 2011, 12:119.
9. Farahmand F., Hill M.F., Singal P.K. Antioxidant and oxidative stress changes in experimental cor pulmonale. Mol. Cell. Biochem. 2004, 260:21-29.
10. Farber H.W. The status of pulmonary arterial hypertension in 2008. Circulation 2008, 117:2966-2968.
11. Fukumoto Y., Matoba T., Ito A., Tanaka H., Kishi T., Hayashidani S., Abe K., Takeshita A., Shimokawa H. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005, 91:391-392.
12. Fukumoto Y., Yamada N., Matsubara H., Mizoguchi M., Uchino K., Yao A., Kihara Y., Kawano M., Watanabe H., Takeda Y., Adachi T., Osanai S., Tanabe N., Inoue T., Kubo A., Ota Y., Fukuda K., Nakano T., Shimokawa H. Double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertension. Circ. J. 2013, 10:2619-2625.
13. Higashi M., Shimokawa H., Hattori T., Hiroki J., Mukai Y., Morikawa K., Ichiki T., Takahashi S., Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ. Res. 2003, 93:767-775.
14. Hoshikawa Y., Ono S., Suzuki S., Tanita T., Chida M., Song C., Noda M., Tabata T., Voelkel N.F., Fujimura S. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J. Appl. Physiol. 2001, 90:1299-1306.
15. 2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
16. Jikimoto T., Nishikubo Y., Koshiba M., Kanagawa S., Morinobu S., Morinobu A., Saura R., Mizuno K., Kondo S., Toyokuni S., Nakamura H., Yodoi J., Kumagai S. Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis. Mol. Immunol. 2002, 38:765-772.
17. Koura T., Gon Y., Hashimoto S., Azuma A., Kudoh S., Fukuda Y., Sugawara I., Yodoi J., Horie T. Expression of thioredoxin in granulomas of sarcoidosis: possible role in the development of T lymphocyte activation. Thorax 2000, 55:755-761.
18. Lai Y.L., Law T.C. Chronic hypoxia- and monocrotaline-induced elevation of hypoxia-inducible factor-1 alpha levels and pulmonary hypertension. J. Biomed. Sci. 2004, 11:315-321.
19. Liu Y., Suzuki Y.J., Day R.M., Fanburg B.L. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ. Res. 2004, 95:579-586.
20. Loirand G., Guerin P., Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ. Res. 2006, 98:322-334.
21. Ma Z., Zhang J., Ji E., Cao G., Li G., Chu L. Rho kinase inhibition by fasudil exerts antioxidant effects in hypercholesterolemic rats. Clin. Exp. Pharmacol. Physiol. 2011, 38:688-694.
22. Mouchaers K.T., Schalij I., de Boer M.A., Postmus P.E., van Hinsbergh V.W., van Nieuw A.G., Vonk N.A., van der Laarse W.J. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur. Respir. J. 2010, 36:800-807.
23. Nakamura H., Hoshino Y., Okuyama H., Matsuo Y., Yodoi J. Thioredoxin 1 delivery as new therapeutics. Adv. Drug Deliv. Rev. 2009, 61:303-309.
24. Oka M., Fagan K.A., Jones P.L., McMurtry I.F. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br. J. Pharmacol. 2008, 155:444-454.
25. Ostadal B., Ressl J., Urbanova D., Prochazka J., Pelouch V., Widimsky J. Effect of verapamil on pulmonary hypertension and right ventricular hypertrophy induced in rats by intermittent high altitude hypoxia. Respiration 1981, 42:221-227.
26. Powis G., Montfort W.R. Properties and biological activities of thioredoxins. Annu. Rev. Biophys. Biomol. Struct. 2001, 30:421-455.
27. Redout E.M., van der Toorn A., Zuidwijk M.J., van de Kolk C.W., van Echteld C.J., Musters R.J., van Hardeveld C., Paulus W.J., Simonides W.S. Antioxidant treatment attenuates pulmonary arterial hypertension-induced heart failure. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H1038-H1047.
28. Rich S. The current treatment of pulmonary arterial hypertension: time to redefine success. Chest 2006, 130:1198-1202.
29. Robertson T.P., Dipp M., Ward J.P., Aaronson P.I., Evans A.M. Inhibition of sustained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and perfused lung of the rat. Br. J. Pharmacol. 2000, 131:5-9.
30. Sakuma K., Nakamura H., Nakamura T., Hoshino Y., Ueda S., Ichikawa M., Tabata C., Fujita S., Masago K., Yodoi J., Mishima M., Mio T. Elevation of serum thioredoxin in patients with gefitinib-induced interstitial lung disease. Intern. Med. 2007, 46:1905-1909.
31. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 2002, 8:S62-S67.
32. Shimokawa H., Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1767-1775.
33. Takahashi K., Chin K., Nakamura H., Morita S., Sumi K., Oga T., Matsumoto H., Niimi A., Fukuhara S., Yodoi J., Mishima M. Plasma thioredoxin, a novel oxidative stress marker, in patients with obstructive sleep apnea before and after nasal continuous positive airway pressure. Antioxid. Redox Signal. 2008, 10:715-726.
34. Takemoto M., Sun J., Hiroki J., Shimokawa H., Liao J.K. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002, 106:57-62.
35. Thomas B.J., Wanstall J.C. Alterations in pulmonary vascular function in rats exposed to intermittent hypoxia. Eur. J. Pharmacol. 2003, 477:153-161.
36. Voelkel N.F., Bogaard H.J., Al H.A., Farkas L., Gomez-Arroyo J., Natarajan R. Antioxidants for the treatment of patients with severe angioproliferative pulmonary hypertension?. Antioxid. Redox Signal. 2013, 18:1810-1817.
37. 2 tension. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:5510-5514.
38. 2+ in pulmonary arterial smooth muscle cells. Circ. Res. 2006, 98:1528-1537.
39. Wang Z., Jin N., Ganguli S., Swartz D.R., Li L., Rhoades R.A. Rho-kinase activation is involved in hypoxia-induced pulmonary vasoconstriction. Am. J. Respir. Cell Mol. Biol. 2001, 25:628-635.
40. Watson W.H., Yang X., Choi Y.E., Jones D.P., Kehrer J.P. Thioredoxin and its role in toxicology. Toxicol. Sci. 2004, 78:3-14.
41. Welsh S.J., Bellamy W.T., Briehl M.M., Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 2002, 62:5089-5095.
42. Welsh S.J., Williams R.R., Birmingham A., Newman D.J., Kirkpatrick D.L., Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol. Cancer Ther. 2003, 2:235-243.
43. Yamada Y., Nakamura H., Adachi T., Sannohe S., Oyamada H., Kayaba H., Yodoi J., Chihara J. Elevated serum levels of thioredoxin in patients with acute exacerbation of asthma. Immunol. Lett. 2003, 86:199-205.
44. Yu A.Y., Frid M.G., Shimoda L.A., Wiener C.M., Stenmark K., Semenza G.L. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am. J. Physiol. 1998, 275:L818-L826.